You are here

Home » Content

Anjiyotensin II Reseptör Antagonisti Losartanın Hipertansif Hemodiyaliz Olgularında Ambulatuar Kan Basıncı Üzerine Etkisi

The effect of Angiotensin II Receptor Antagonist Losartan on Ambulatory Blood Pressure in Hypertensive Hemodialysis Cases

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
In this study, the effect of angiotensin II receptor antagonist losartan on ambulatory blood pressure (ABP) in 28 hypertensive hemodialysis cases was investigated. The cases were divided into two groups. Seventeen cases in losartan group received 50 to 100 mg/day losartan for 16 weeks. Eleven cases in control group did not receive any medication. In all cases, predialysis 24-hour ABP monitoring was performed just before and after the treatment. In the losartan group, when posttreatment changes in the 24-hour, daytime and nighttime systolic blood pressure (SPB) and diastolic blood pressure (DBP) values compared with pretreatment, the values except daytime SBP were significant decreased. But, there was only a difference between the changes in nighttime SBP and DBP when compared with control group (-%6 ± 9 vs %1 ± 4 and -%8 ± 12 vs %1 ± 7, p>0.05, respectively). After the treatment, the SBP reading rate between 140 to 160 mmHg (20%) in the losartan group was lower than the rate of the control group (70%). The diurnal variations of two cases in the losartan group were improved. The percentages of nighttime SBP reading >140 mmHg, and 24-hour and nighttime DBP readings >90 mmHg in the losartan group were significantly decreased. All cases tolerated losartan therapy well. As a result, we concluded that losartan lowered blood pressure and pressure load in hypertensive hemodialysis cases and provided better nighttime blood pressure control.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, 28 hipertansif hemodiyaliz olgusunda anjiyotensin reseptör antagonisti losartanın ambulatuar kan basıncı (AKB) üzerine etkisi araştırıldı. Olgular 2 gruba ayrıldılar. Losartan grubundaki 17 olgu 16 hafta boyunca 50-100 mg/gün losartan tedavisi aldı. Kontrol grubundaki 11 olgu ise herhangi bir tedavi almadı. Tüm olgularda hemen tedavi öncesi ve sonrası prediyaliz 24 saatlik AKB takibi yapıldı. Losartan grubunda 24 saatlik, gün boyu ve gece boyu sistolik kan basıncı (SKB) ve diyastolik kan basıncı (DKB) değerlerindeki tedavi sonrası değişiklikler tedavi öncesi ile karşılaştırıldığında, gün boyu SKB dışındakiler anlamlı olarak azaldı. Fakat kontrol grubu ile karşılaştırıldığında sadece gece boyu ortalama SKB ve DKB’ndaki değişiklikler arasında fark vardı (sırasıyla -%6 ± 9’a karşılık %1 ± 4 ve -%8 ± 12’ye karşılık %1 ± 7, p>0.05). Tedavi sonrası losartan grubunda SKB’nı 140 ile 160 mmHg arasında okuma oranı (%20), kontrol grubundan (%70) daha düşüktü. Losartan grubundaki iki olgunun diurnal varyasyonu düzeldi. Losartan grubunda gece boyu SKB’nı >140 mmHg ve 24 saatlik ve gece boyu DKB’nı >90 mmHg okuma yüzdeleri anlamlı azaldı. Losartan tedavisi olgular tarafından iyi tolere edildi. Sonuç olarak, hipertansif hemodiyaliz olgularında losartanın kan basıncını ve basınç yükünü azalttığı ve daha iyi gece boyu kan basıncı kontrolü sağladığı kanaatine vardık.
FULL TEXT (PDF): 
PDF icon arastirmax-anjiyotensin-ii-reseptor-antagonisti-losartanin-hipertansif-hemodiyaliz-olgularinda-ambulatuar-kan-basinci-uzerine-etkisi.pdf
  • 2
11-16
  • Turkish

REFERENCES

References: 

1. Campese VM, Bigazzi R. Hypertension in chronic renal failure,
dialysis, and transplantation. In: Glassock RJ (ed). Current
Therapy in Nephrology and Hypertension. St. Louis:
Mosby-Year Book Inc.; 1992. 391-405. A.Ersoy, ark.
16
2. Ertürk Ş. Hipertansiyon. Akpolat T, Utaş C (eds). Hemodiyaliz
Hekimi El Kitabı. Kayseri: Anadolu Yayıncılık; 2001. 184-
6.
3. Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left
ventricular hypertrophy and long-term prognosis in
hemodialysis patients. Kidney Int 1998; 54(Suppl.68): S92-
8.
4. Amann K, Rychlik I, Miherberger-Milteny G, Ritz E. Left
ventricular hypertrophy in renal failure. Kidney Int 1998;
54(Suppl.68): S78-85.
5. Scribner BH. Can antihypertensive medications control BP in
haemodialysis patients: yes or no? Nephrol Dial Transplant
1999; 14: 2599-601.
6. Salem MM. Hypertension in the hemodialysis population: A
survey of 649 patients. Am J Kidney Dis 1995; 26: 461-8.
7. Salem MM, Bower J. Hypertension in the hemodialysis
population: Any relation to one-year survival? Am J
Kidney Dis 1996; 28: 737-40.
8. Johnston CI. Angiotensin receptor antagonists: Focus on losartan.
Lancet 1995; 346: 1403-7.
9. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of
losartan potassium and angiotensin II receptor antagonist,
compared with hydrochlorothiazide, atenolol, felodipine
ER, and angiotensin-converting enzyme inhibitors for the
treatment of systemic hypertension. Am J Cardiol 1995;
75: 793-5.
10. Weber M. Clinical safety and tolerability of losartan. Clin Ther
1997; 19: 604-16.
11. Verresen L, Waer M, Vanrenterghem Y, Michielsen P.
Angiotensin-converting-enzyme inhibitors and
anaphylactoid reactions to high-flux membrane dialysis.
Lancet 1990; 336: 1360-2.
12. Mcintyre M, Caffe SE, Michalak RA, Reid JL. Losartan, an orally
active angiotensin (AT(1)) receptor antagonist: A review of
its efficacy and safety in essential hypertension.
Pharmacology Therapeutics 1997; 74: 181-94.
13. Saracho R, Martin-Malo A, Martinez I et al. Evaluation of the
losartan in hemodialysis (ELHE) study. Kidney Int 1998;
54(Suppl.68): S125-9.
14. 1999 World Health Organisation International Society of
Hypertension Guide lines for the management of
hypertension. Guidelines Subcommittee. J Hypertens 1999;
17: 151-83.
15. Toto R, Shultz P, Raij L et al. Efficacy and tolerability of losartan
in hypertensive patients with renal impairment.
Hypertension 1998; 31: 684-91.
16. Fernandez-Andrade C, Russo D, Iversen B. Comparison of
losartan and amlodipine in renally impaired hypertensive
patients. Kidney Int 1998; 54(Suppl.68): S120-4.
17. Joint National Committee on Detection, Evaluation and
Treatment of High Blood Pressure: The Sixth Report of the
Joint National Committee on Detection, Evaluation, and
Treatment of High Blood Pressure. NIH/NHLBI. Arch
Intern Med 1997; 157: 2413-46.
18. National High Blood Pressure Education Program Working
Group: 1995 Update of the working group reports on
chronic renal failure and renovascular hypertension. Arch
Intern Med 1996; 156: 1938-47.
19. Cheigh JS. What are the unique aspects of antihypertensive
therapy in dialysis patients? Semin Dial 1994; 7: 170-2.
20. Highlights from the 1996 Core Indicators Project for
hemodialysis patients. HEFA. Dial Transplant 1997; 26:
188-95.
21. Mailloux LU, Haley WE. Hypertension in the ESRD patient:
Pathophysiology, therapy outcomes, and future directions.
Am J Kidney Dis 1998; 32: 705-19.
22. Raine A, Margreiter R, Brunner F. Report on management of
renal failure in Europe, XXII, 1991. Nephrol Dial
Transplant 1992; 2: 7-35.
23. Rahman M, Dixit A, Donley V et al. Factors associated with
inadequate blood pressure control in hypertensive
hemodialysis patients. Am J Kidney Dis 1999; 33: 498-
506.
24. Martinez-Maldonado M: Hypertension in end-stage renal disease.
Kidney Int 1998; 54(Suppl.68): S67-72.
25. Cheigh JS, Milite C, Sullivan JF et al. Hypertension is not
adequately controlled in hemodialysis patients. Am J
Kidney Dis 1992; 19: 453-9.
26. Ritz E, Strumpf C, Katz F, Wing AJ, Quellhorst E. Hypertension
and cardiovascular risk factors in hemodialyzed diabetic
patients. Hypertension 1985; 7: 118-24.
27. Savage T, Fabbian F, Giles M, Tomson CRV, Raine AEG.
Interdialytic weigh gain and 48-h blood pressure in
haemodialysis patients. Nephrol Dial Transplant 1997; 12:
2308-11.
28. Maschio G. Erythropoietin and systemic hypertension. Nephrol
Dial Transplant 1995; 10: 74-9.
29. Charra B. Control of blood pressure by long slow haemodialysis.
Blood Purif 1994; 12: 252-8.
30. MacAllister R, Vallance P. Nitric oxide in essential and renal
hypertension. J Am Soc Nephrol 1994; 5: 1057-65.
31. Herrera-Acasta J. Hypertension in chronic renal disease. Kidney
Int 1992; 22: 702-12.
32. Vertes V, Cangiano JL, Berman LB et al. Hypertension in endstage renal disease. N Engl J Med 1969; 280: 978-81.
33. Converse RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med
1992; 32: 1912-8.
34. Arık N. Giriş, tanımlamalar ve kan basıncı ölçümü. Arık N,
Korkmaz M (eds). Hipertansiyon. İstanbul: Format Matbaacılık; 1999. 10-4.
35. Farmer CKT, Goldsmith DJA, Cox J et al. An investigation of the
effect of advancing uraemia, renal replacement therapy and
renal transplantation on blood pressure diurnal variability.
Nephrol Dial Transplant 1997; 12: 2301-7.
36. The SAMPLE Study Group: Ambulatory blood pressure is
superior to clinic blood pressure in predicting treatmentinduced regression of left ventricular hypertrophy.
Circulation 1997; 95: 1464-70.
37. Fogari R, Zoppi A, Mugellini A et al. Comparative efficacy of
losartan and valsartan in mild-to-moderate hypertension:
Results of 24-hour ambulatory blood pressure monitoring.
Curr Therapeutic Res 1999; 60: 195-206.
38. Verdecchia P, Schillaci G, Guerrini M et al. Circadien blood
pressure changes and left ventricular hypertrophy in
essential hypertension. Circulation 1991; 81: 528-36.

Thank you for copying data from http://www.arastirmax.com